{"id":751452,"date":"2023-04-26T11:16:41","date_gmt":"2023-04-26T15:16:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/"},"modified":"2023-04-26T11:16:41","modified_gmt":"2023-04-26T15:16:41","slug":"contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/","title":{"rendered":"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee"},"content":{"rendered":"
\n

YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation<\/strong><\/a> (Nasdaq: CFRX)<\/strong>, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b\/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus<\/em> (S. aureus<\/em>) or Coagulase-Negative Staphylococci (CoNS).<\/p>\n

\u201cWe are pleased by the rapid enrollment of the first patient in our PJI study of exebacase,\u201d said Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. \u201cIt is important to understand that surgical revision of the infected prosthesis, the current standard of care for chronic PJI, has barely improved clinical outcomes over the past several decades. We believe exebacase has the potential to replace this debilitating and expensive surgical procedure, eradicate the infection, and significantly improve quality of life for patients with chronic PJIs suffering from pain and loss of mobility.\u201d<\/p>\n

The Phase 1b\/2 study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in France to assess the safety, pharmacokinetics (PK), and efficacy of intra-articularly administered exebacase in patients with chronic PJI of the knee due to S. aureus<\/em> or CoNS. The study will be conducted in two parts. Part I will assess efficacy at an early, six-week timepoint in addition to safety and PK. Part II will be a long-term clinical safety and efficacy follow-up for a period of up to two years. Patients entering the study will be randomized 3:1 to either exebacase or placebo, with all patients receiving study drug in the setting of a DAIR Procedure.<\/p>\n

Data from compassionate use cases is available in the Publications & Posters<\/a> and Presentations<\/a> sections of the Company\u2019s website.<\/p>\n

\n About ContraFect<\/strong>\n <\/p>\n

ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including\u00a0P. aeruginosa<\/em>,\u00a0Acinetobacter baumannii<\/em>, and\u00a0Enterobacter<\/em>\u00a0species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and\u00a0P. aeruginosa<\/em>, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of\u00a0Staph aureus<\/em>\u00a0bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.<\/p>\n

Follow ContraFect on Twitter @ContraFectCorp<\/a> and LinkedIn<\/a>.<\/p>\n

\n F<\/strong>
\n orward-Looking Statements <\/strong>\n <\/p>\n

This press release contains, and our officers and representatives may make from time to time, \u201cforward-looking statements\u201d within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as \u201cprojects,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cpromise\u201d or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding the Phase 1b\/2 clinical study, patient dosing and patient enrollment, statements made by Dr. Pomerantz, whether exebacase has the potential to replace surgical revision, eradicate infection, and significantly improve quality of life for patients with chronic PJIs, ContraFect\u2019s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using therapeutic candidates from its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect\u2019s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa<\/em>. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect\u2019s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect\u2019s control, including, without limitation, that ContraFect has and expects to continue to incur significant losses, ContraFect\u2019s need for additional funding, which may not be available, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect\u2019s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection, changes in management may negatively affect ContraFect\u2019s business and other important risks detailed under the caption \u201cRisk Factors\u201d in ContraFect’s Annual Report on Form 10-K for the year ended December 31, 2022 and its other filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n

\n Investor Relations Contacts:<\/strong>\n <\/p>\n

Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b\/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS). \u201cWe are pleased by the rapid enrollment of the first patient in our PJI study of exebacase,\u201d said Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of … <\/p>\n

Continue reading “ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751452","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b\/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS). \u201cWe are pleased by the rapid enrollment of the first patient in our PJI study of exebacase,\u201d said Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of … Continue reading "ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T15:16:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ContraFect Announces First Patient Dosed in the Phase 1b\\\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee\",\"datePublished\":\"2023-04-26T15:16:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/\"},\"wordCount\":1070,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/\",\"name\":\"ContraFect Announces First Patient Dosed in the Phase 1b\\\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=\",\"datePublished\":\"2023-04-26T15:16:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ContraFect Announces First Patient Dosed in the Phase 1b\\\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/","og_locale":"en_US","og_type":"article","og_title":"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee - Market Newsdesk","og_description":"YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b\/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS). \u201cWe are pleased by the rapid enrollment of the first patient in our PJI study of exebacase,\u201d said Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of … Continue reading \"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T15:16:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee","datePublished":"2023-04-26T15:16:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/"},"wordCount":1070,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/","name":"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=","datePublished":"2023-04-26T15:16:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEwNSM1NTU4ODQ4IzIwOTE5NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contrafect-announces-first-patient-dosed-in-the-phase-1b-2-study-of-exebacase-in-patients-with-chronic-prosthetic-joint-infections-of-the-knee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751452"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751452\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}